MY202406A - Oxazole compound crystal - Google Patents

Oxazole compound crystal

Info

Publication number
MY202406A
MY202406A MYPI2020005118A MYPI2020005118A MY202406A MY 202406 A MY202406 A MY 202406A MY PI2020005118 A MYPI2020005118 A MY PI2020005118A MY PI2020005118 A MYPI2020005118 A MY PI2020005118A MY 202406 A MY202406 A MY 202406A
Authority
MY
Malaysia
Prior art keywords
oxazole compound
crystal
compound crystal
specific
peaks
Prior art date
Application number
MYPI2020005118A
Other languages
English (en)
Inventor
Naohiko Kanai
Takayuki Yasutomi
Ryosuke Hirota
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MY202406A publication Critical patent/MY202406A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI2020005118A 2018-04-04 2019-04-03 Oxazole compound crystal MY202406A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018072717 2018-04-04
PCT/JP2019/014730 WO2019194211A1 (en) 2018-04-04 2019-04-03 Oxazole compound crystal

Publications (1)

Publication Number Publication Date
MY202406A true MY202406A (en) 2024-04-27

Family

ID=66223774

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020005118A MY202406A (en) 2018-04-04 2019-04-03 Oxazole compound crystal

Country Status (26)

Country Link
US (4) US11414391B2 (cg-RX-API-DMAC7.html)
EP (2) EP4400167A3 (cg-RX-API-DMAC7.html)
JP (4) JP7326295B2 (cg-RX-API-DMAC7.html)
KR (2) KR102764726B1 (cg-RX-API-DMAC7.html)
CN (1) CN111902402B (cg-RX-API-DMAC7.html)
AU (2) AU2019249562B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020019377A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095866A1 (cg-RX-API-DMAC7.html)
DK (1) DK3774745T3 (cg-RX-API-DMAC7.html)
EA (1) EA202092393A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982586T3 (cg-RX-API-DMAC7.html)
FI (1) FI3774745T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240858T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066793T2 (cg-RX-API-DMAC7.html)
IL (2) IL315425A (cg-RX-API-DMAC7.html)
LT (1) LT3774745T (cg-RX-API-DMAC7.html)
MX (1) MX2020010435A (cg-RX-API-DMAC7.html)
MY (1) MY202406A (cg-RX-API-DMAC7.html)
PH (1) PH12020551605A1 (cg-RX-API-DMAC7.html)
PL (1) PL3774745T3 (cg-RX-API-DMAC7.html)
PT (1) PT3774745T (cg-RX-API-DMAC7.html)
SG (1) SG11202009564TA (cg-RX-API-DMAC7.html)
SI (1) SI3774745T1 (cg-RX-API-DMAC7.html)
TW (2) TWI860993B (cg-RX-API-DMAC7.html)
WO (1) WO2019194211A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006134B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3774745T3 (pl) * 2018-04-04 2024-08-19 Otsuka Pharmaceutical Co., Ltd. Kryształ cząsteczki oksazolu
EP4501324A4 (en) 2022-03-25 2026-04-08 Otsuka Pharma Co Ltd WOUND TREATMENT COMPOSITION
CN115887463A (zh) * 2022-12-27 2023-04-04 瑞石生物医药有限公司 一种含环酰胺化合物的药物组合物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
US20260076788A1 (en) * 2024-09-17 2026-03-19 Natalie DeVoir Orthodontic composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI330639B (en) * 2005-11-15 2010-09-21 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
EP2890686B1 (en) * 2012-08-30 2017-01-04 Otsuka Pharmaceutical Co., Ltd. Method for producing oxazole compound
TWI726027B (zh) * 2015-12-28 2021-05-01 日商大塚製藥股份有限公司 軟膏
PL3774745T3 (pl) * 2018-04-04 2024-08-19 Otsuka Pharmaceutical Co., Ltd. Kryształ cząsteczki oksazolu

Also Published As

Publication number Publication date
AU2019249562B2 (en) 2024-06-27
AU2024220015A1 (en) 2024-10-17
MX2020010435A (es) 2020-10-28
CA3095866A1 (en) 2019-10-10
IL277730B1 (en) 2024-10-01
IL315425A (en) 2024-11-01
JP2024001115A (ja) 2024-01-09
WO2019194211A1 (en) 2019-10-10
TW202012380A (zh) 2020-04-01
EP4400167A2 (en) 2024-07-17
US20250250243A1 (en) 2025-08-07
EP3774745B1 (en) 2024-05-29
EP3774745A1 (en) 2021-02-17
ZA202006134B (en) 2023-03-29
IL277730B2 (en) 2025-02-01
AU2019249562A1 (en) 2020-10-22
KR20250022254A (ko) 2025-02-14
US20210147370A1 (en) 2021-05-20
JP2021517111A (ja) 2021-07-15
PH12020551605A1 (en) 2021-04-26
TW202515853A (zh) 2025-04-16
JP7326295B2 (ja) 2023-08-15
LT3774745T (lt) 2024-07-10
CN111902402A (zh) 2020-11-06
JP2025128238A (ja) 2025-09-02
SI3774745T1 (sl) 2024-08-30
US20240076275A1 (en) 2024-03-07
IL277730A (en) 2020-11-30
JP2022037040A (ja) 2022-03-08
BR112020019377A2 (pt) 2021-01-05
CN111902402B (zh) 2026-07-14
SG11202009564TA (en) 2020-10-29
HRP20240858T1 (hr) 2024-10-11
FI3774745T3 (fi) 2024-06-19
PL3774745T3 (pl) 2024-08-19
ES2982586T3 (es) 2024-10-16
US11840512B2 (en) 2023-12-12
EP4400167A3 (en) 2024-09-25
US20220411386A1 (en) 2022-12-29
PT3774745T (pt) 2024-06-25
HUE066793T2 (hu) 2024-09-28
EA202092393A1 (ru) 2021-01-25
TWI860993B (zh) 2024-11-11
US11414391B2 (en) 2022-08-16
KR102764726B1 (ko) 2025-02-11
AU2024220015B2 (en) 2026-03-26
DK3774745T3 (da) 2024-06-17
KR20200139736A (ko) 2020-12-14

Similar Documents

Publication Publication Date Title
PH12020551605A1 (en) Oxazole compound crystal
GEAP202416125A (en) Microbiocidal derivatives
MX2021006099A (es) Derivados de tiazol microbiocidas.
GEP20237506B (en) Pcsk9 antagonist compounds
GEP201706692B (en) Biaryl amide compounds as kinase inhibitors
GEAP202215479A (en) Magl inhibitors
PH12019550224A1 (en) Antitumoral compounds
FI4349406T3 (fi) 6-karboksi-2-(3,5-dikloorifenyyli)-bentsoksatsolin kiteisiä kiinteitä muotoja käytettäväksi lääkkeenä
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
RU2016146119A (ru) Новый кристалл тетрациклического соединения
MX2021000941A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos.
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
IN2014CN00689A (cg-RX-API-DMAC7.html)
ZA202101487B (en) Novel compounds
NZ743699A (en) 1,3,4-thiadiazole compounds and their use in treating cancer
PH12018501346B1 (en) Ointment
PH12018501132A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
PH12022551403A1 (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine.
MY202100A (en) Crystal
SG11201809127PA (en) Crystalline polymorph of 15b-hydroxy-osaterone acetate
EA202192903A1 (ru) Кристаллическая форма ингибитора plk4
AU2019408336A8 (en) Phenylpyrrolidine compound and use thereof
MX2020012747A (es) Compuestos de uracilo y su uso.
AR107441A1 (es) Forma cristalina de cobicistat
PH12022551548A1 (en) Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof